Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer
Background: Emerging evidence suggests that the immune system plays a crucial role in the regulation of the response to therapy and long-term outcomes of patients with breast cancer (BRCA). In this study, we aimed to identify a significant signature based on immune-related genes to predict the progn...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fgene.2020.00912/full |
id |
doaj-3f10f60f7b8240c4a695cfc01812c264 |
---|---|
record_format |
Article |
spelling |
doaj-3f10f60f7b8240c4a695cfc01812c2642020-11-25T03:55:04ZengFrontiers Media S.A.Frontiers in Genetics1664-80212020-09-011110.3389/fgene.2020.00912534447Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast CancerJianying Pei0Jianying Pei1Yan Li2Tianxiong Su3Qiaomei Zhang4Xin He5Dan Tao6Yanyun Wang7Manqiu Yuan8Yanping Li9Yanping Li10Department of Clinical Laboratory, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaInstitute of Clinical Medicine, Gansu Province Maternal and Child-Care Hospital, Lanzhou, ChinaGuangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaDepartment of Clinical Laboratory, People’s Hospital of Qingyang, Qingyang, ChinaDepartment of Hematology, The First Hospital of Lanzhou University, Lanzhou, ChinaDepartment of Clinical Laboratory, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaDepartment of Clinical Laboratory, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaDepartment of Clinical Laboratory, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaDepartment of Clinical Laboratory, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaDepartment of Clinical Laboratory, The First Clinical Medical College of Lanzhou University, Lanzhou, ChinaDepartment of Clinical Laboratory, The First Hospital of Lanzhou University, Lanzhou, ChinaBackground: Emerging evidence suggests that the immune system plays a crucial role in the regulation of the response to therapy and long-term outcomes of patients with breast cancer (BRCA). In this study, we aimed to identify a significant signature based on immune-related genes to predict the prognosis of BRCA patients.Methods: The expression data were downloaded from The Cancer Genome Atlas (TCGA). The immune-related gene list, the transcription factor (TF) gene list, and the immune infiltrate scores of samples in the TCGA database were acquired from the ImmPort database, the Cistrome Cancer database, and the TIMER database, respectively. Univariate Cox regression analysis was utilized to identify prognostic immune-related differentially expressed genes (DEGs) (PIRDEGs) in BRCA. A prognostic immune signature containing 15 PIRDEGs in BRCA was established using the least absolute shrinkage and selection operator (LASSO) model with 1,000 iterations followed by a stepwise Cox proportional hazards model with a training set of 508 samples in TCGA. An independent assessment of the prognostic prediction ability of the signature was conducted using Kaplan–Meier survival analysis with a testing set of 505 samples in TCGA.Results: We identified 466 PIRDEGs and 80 TFs among the DEGs. A gene signature containing 15 PIRDEGs was constructed. Risk scores of BRCA patients were calculated using this model, which showed a high accuracy of prognosis prediction in both the training set and testing set and could be an independent prognostic factor of BRCA patients.Conclusions: Our study revealed that a PIRDEG signature could be a candidate prognostic biomarker for predicting the overall survival (OS) of patients with BRCA.https://www.frontiersin.org/article/10.3389/fgene.2020.00912/fullbreast cancerimmune-related genestranscription factorsprognosisrisk-score model |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jianying Pei Jianying Pei Yan Li Tianxiong Su Qiaomei Zhang Xin He Dan Tao Yanyun Wang Manqiu Yuan Yanping Li Yanping Li |
spellingShingle |
Jianying Pei Jianying Pei Yan Li Tianxiong Su Qiaomei Zhang Xin He Dan Tao Yanyun Wang Manqiu Yuan Yanping Li Yanping Li Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer Frontiers in Genetics breast cancer immune-related genes transcription factors prognosis risk-score model |
author_facet |
Jianying Pei Jianying Pei Yan Li Tianxiong Su Qiaomei Zhang Xin He Dan Tao Yanyun Wang Manqiu Yuan Yanping Li Yanping Li |
author_sort |
Jianying Pei |
title |
Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer |
title_short |
Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer |
title_full |
Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer |
title_fullStr |
Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer |
title_full_unstemmed |
Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer |
title_sort |
identification and validation of an immunological expression-based prognostic signature in breast cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Genetics |
issn |
1664-8021 |
publishDate |
2020-09-01 |
description |
Background: Emerging evidence suggests that the immune system plays a crucial role in the regulation of the response to therapy and long-term outcomes of patients with breast cancer (BRCA). In this study, we aimed to identify a significant signature based on immune-related genes to predict the prognosis of BRCA patients.Methods: The expression data were downloaded from The Cancer Genome Atlas (TCGA). The immune-related gene list, the transcription factor (TF) gene list, and the immune infiltrate scores of samples in the TCGA database were acquired from the ImmPort database, the Cistrome Cancer database, and the TIMER database, respectively. Univariate Cox regression analysis was utilized to identify prognostic immune-related differentially expressed genes (DEGs) (PIRDEGs) in BRCA. A prognostic immune signature containing 15 PIRDEGs in BRCA was established using the least absolute shrinkage and selection operator (LASSO) model with 1,000 iterations followed by a stepwise Cox proportional hazards model with a training set of 508 samples in TCGA. An independent assessment of the prognostic prediction ability of the signature was conducted using Kaplan–Meier survival analysis with a testing set of 505 samples in TCGA.Results: We identified 466 PIRDEGs and 80 TFs among the DEGs. A gene signature containing 15 PIRDEGs was constructed. Risk scores of BRCA patients were calculated using this model, which showed a high accuracy of prognosis prediction in both the training set and testing set and could be an independent prognostic factor of BRCA patients.Conclusions: Our study revealed that a PIRDEG signature could be a candidate prognostic biomarker for predicting the overall survival (OS) of patients with BRCA. |
topic |
breast cancer immune-related genes transcription factors prognosis risk-score model |
url |
https://www.frontiersin.org/article/10.3389/fgene.2020.00912/full |
work_keys_str_mv |
AT jianyingpei identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT jianyingpei identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT yanli identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT tianxiongsu identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT qiaomeizhang identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT xinhe identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT dantao identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT yanyunwang identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT manqiuyuan identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT yanpingli identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer AT yanpingli identificationandvalidationofanimmunologicalexpressionbasedprognosticsignatureinbreastcancer |
_version_ |
1724470963749257216 |